Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19692
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChin-Lenn, L-
dc.contributor.authorDe Boer, R H-
dc.contributor.authorSegelov, E-
dc.contributor.authorMarx, G M-
dc.contributor.authorHughes, T M-
dc.contributor.authorMcCarthy, N J-
dc.contributor.authorWhite, Shane C-
dc.contributor.authorFoo, S S-
dc.contributor.authorRutovitz, J J-
dc.contributor.authorDella-Fiorentina, S-
dc.contributor.authorJennens, R-
dc.contributor.authorAntill, Y C-
dc.contributor.authorTsoi, D-
dc.contributor.authorCronk, M F-
dc.contributor.authorLombard, J M-
dc.contributor.authorKiely, B E-
dc.contributor.authorChirgwin, J H-
dc.contributor.authorGorelik, A-
dc.contributor.authorMann, G B-
dc.date2018-09-30-
dc.date.accessioned2018-10-23T22:28:43Z-
dc.date.available2018-10-23T22:28:43Z-
dc.date.issued2018-12-
dc.identifier.citationAsia-Pacific Journal of Clinical Oncology 2018; 14(6): 410-416-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19692-
dc.description.abstractIndustry-supported decision impact studies demonstrate that Oncotype Dx (ODX) changes treatment recommendations (TR) in 24-40% of hormone receptor+/HER2- patients. ODX is not reimbursed by third-party payers in Australia, potentially resulting in more selective use. We sought to evaluate the impact of self-funded ODX on TRs. Data collected included demographics, tumor characteristics, indication for ODX and pre- and post-recurrence score (RS) TR. Primary endpoint was frequency of TR change and associations with TR change were sought. Eighteen physicians contributed 382 patients (median age 54). A total of 232 (61%) of tumors were T1 and were grade 1, 2 and 3 in 49 (13%), 252 (66%) and 79 (21%). A total of 257 (67%) were node negative. Assay indications were: confirm need for chemotherapy (CT) (36%), confirm omission of CT (40%) and genuine equipoise (24%). RS was low (≤17) in 55%, intermediate (18-31) in 36% and high (≥32) in 9%. Thirty-eight percent of patients had TR change post-ODX. Sixty-five percent of patients recommended CT pre-ODX changed to hormone therapy alone (HT)-more likely if lower grade and if ER and/or PR > 10%. Fourteen percent of patients with pre-ODX TR for HT added CT-more likely if ER and/or PR ≤10% and if Ki67 > 15% Overall, TR for CT decreased from 47% to 24%. Patient-funded ODX changed TRs in 38% of patients, de-escalating 65% from CT to HT and adding CT to 14% of those recommended HT. These changes were greater than an industry-funded study suggesting that physicians can identify situations where the assay may influence decisions.-
dc.language.isoeng-
dc.subjectHER2-negative early Breast cancer-
dc.subjectadjuvant chemotherapy-
dc.subjecthormone receptor-positive-
dc.subjectmultigene assay-
dc.subjecttreatment decision-
dc.titleThe impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable.-
dc.typeJournal Article-
dc.identifier.journaltitleAsia-Pacific Journal of Clinical Oncology-
dc.identifier.affiliationEastern Health, Box Hill, Victoria, Australiaen
dc.identifier.affiliationSunshine Coast Hospital and Health Services, Nambour, QLD, Australiaen
dc.identifier.affiliationCalvary Mater Newcastle, Waratah, NSW, Australiaen
dc.identifier.affiliationMacarthur Cancer Therapy Centre, Campbelltown, NSW, Australiaen
dc.identifier.affiliationThe Royal Melbourne Hospital, Parkville, Victoria, Australiaen
dc.identifier.affiliationRoyal Women's Hospital, Parkville, Victoria, Australiaen
dc.identifier.affiliationSydney Adventist Hospital, Wahroonga, NSW, Australiaen
dc.identifier.affiliationUniversity of Sydney, Sydney, NSW, Australiaen
dc.identifier.affiliationICON Cancer Care Wesley, Auchenflower, QLD, Australiaen
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationEpworth Eastern Hospital, Box Hill, Victoria, Australiaen
dc.identifier.affiliationSt Vincent's Private Hospital, East Melbourne, Victoria, Australiaen
dc.identifier.affiliationNorthern Haematology and Oncology Group, Wahroonga, NSW, Australiaen
dc.identifier.affiliationEpworth Hospital, East Melbourne, Australiaen
dc.identifier.affiliationCabrini Health, Malvern, Victoria, Australiaen
dc.identifier.affiliationSt John of God Murdoch Hospital, Murdoch, Victoria, Australiaen
dc.identifier.doi10.1111/ajco.13075-
dc.identifier.orcid0000-0001-6445-6849-
dc.identifier.pubmedid30270527-
dc.type.austinJournal Article-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.